Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer

Conditions

• Carcinoma, Squamous Cell
• Head and Neck Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Erlotinib — DRUG
  loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin

Study Details

The purpose of this study is to determine if combination Erlotinib, Cisplatin/Carboplatin, and Paclitaxel are effective first line treatment for metastatic, recurrent and persistent squamous cell carcinoma of the head and neck.

Key Dates

First listed

Mar 16, 2007

Start date

Feb 28, 2007

Status verified

Feb 2025

Primary completion

Jan 31, 2012

Completion

Jan 31, 2012

Study Design

Enrollment

6 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Erlotinib
  Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo

Primary Outcome Measure

Tumor Response Rate of Intermittent Tarceva During First Line Standard Platinum Containing Chemotherapy [ Time Frame: Evaluated at 6-week intervals, up to an average of 18 weeks. ]

Related Studies

• Identification and Characterization of Novel Proteins and Genes in Head and Neck Cancer
  Recruiting · Stanford University · Stanford, California
• Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
  Recruiting · Stanford University · Stanford, California
• Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
  Recruiting · Vanderbilt University Medical Center · Nashville, Tennessee
• Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
  Recruiting · University of Colorado, Denver · Aurora, Colorado